Clinical trials: Multiple System Atrophy (MSA)
Parkinson Disease, MSA - Multiple System Atrophy
Differential Diagnosis Between Parkinson's Disease and Multiple System Atrophy Using Digital Speech Analysis
Parkinson's disease (PD) is the second most common neurodegenerative disease. Multiple system atrophy (MSA) is a relentlessly progressing rare neurodegenerative disease of unknown etiology.
- Trial name
- Voice4PD-MSA (NCT03577483)
- Testing
- voice recordings
- Where
- 2 sites in France
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Multiple System Atrophy - Parkinsonian Subtype (MSA-P), Multiple System Atrophy - Cerebellar Subtype (MSA-C)
PET Imaging Study of Neurochemical and Autonomic Disorders in Multiple System Atrophy (MSA)
Multiple system atrophy (MSA) is a disorder of the nervous system of unclear cause. In MSA there is degeneration (progressive loss) of nerve cells in several brain and spinal cord regions.
- Trial name
- NCT02035761
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Michigan
Multiple System Atrophy
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
A Phase 2a Study of Foralumab Nasal in Patients with Multiple System Atrophy (MSA)
- Trial name
- NCT06868628
- Testing
- Foralumab Nasal
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Tiziana Life Sciences LTD
Multiple System Atrophy
Inosine 5'-Monophosphate to Raise of Serum Uric Acid Level in Patients With Multiple System Atrophy: a Multi-center, Randomized Controlled, Double Blind, Parallel Assigned Clinical Trial
A purpose of the present study is to investigate the capability of serum uric acid elevation, safety, and tolerability of inosine 5'-monophosphate in patients with multiple system atrophy with multicenter, randomized, placebo…
- Trial name
- NCT03403309
- Testing
- 1) Inosine 5'-monophosphate
- Where
- South Korea
- Volunteers
- 43 people
- Sponsor
- Yonsei University
Atypical Parkinsonism, MSA - Multiple System Atrophy
Integrated Management of Atypical Parkinsonism: A Home-based Patient-Centered Healthcare Delivery Based on Telenursing (IMPACT Study)
This project aims to investigate whether an integrated model based on proactive and reactive telenursing monitoring coordinated by a parkinsonism nurse specialist (case manager) is able to improve care delivery and quality of…
- Conditions
- Atypical Parkinsonism, MSA - Multiple System Atrophy, PSP, Nurse-Patient Relations
- Trial name
- NCT05792332
- Testing
- Telemonitoring, Standard-of-care
- Where
- 4 sites in Italy
- Volunteers
- 164 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Sleep Apnea Syndromes, Multiple System Atrophy
Assessment of Ambulatory Polygraphy in the Detection of Sleep Apnea in Multiple System Atrophy (SAMSA)
The purpose of this study is to determine whether ambulatory polygraphy during a short hospitalization in a neurology unit has the same performance than inpatient polysomnography, the actual gold standard, in the diagnosis of…
- Trial name
- NCT00743561
- Testing
- Polysomnography, ambulatory polygraphy
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Bordeaux
Multiple System Atrophy (MSA)
Multiple System Atrophy Multidisciplinary Clinic
This is a prospective cohort study to examine the disease burden of multiple system atrophy and the impact of multidisciplinary care on quality of life and caregiver burden.
- Trial name
- NCT03811808
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Texas Southwestern Medical Center
Multiple System Atrophy
Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA
Evaluate the effects of L-Threo DOPS on orthostatic hypotension symptoms and other non-motor symptoms in patients with Multiple System Atrophy (MSA) after 12 weeks following randomization to continued therapy with droxidopa or…
- Trial name
- DOPS-AMS (NCT02071459)
- Testing
- L-Threo DOPS
- Where
- 13 sites in France
- Volunteers
- 107 people
- Sponsor
- University Hospital, Toulouse
Progressive Supranuclear Palsy, Multiple System Atrophy
Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)
In total 20 subjects will be enrolled at one participating site -UMC Ljubljana. The 20 subjects will be treated with placebo and NBMI 300 mg in a cross-over design.
- Trial name
- EMERA006 (NCT04184063)
- Testing
- NBMI
- Where
- Slovenia
- Volunteers
- 20 people
- Sponsor
- EmeraMed
Multiple System Atrophy (MSA)
Oligomeric Alpha-synuclein in Multiple System Atrophy
The main objectives are to determine on one hand whether oligomeric alpha-synuclein levels are increased in MSA patients compared to controls and on other hand whether there is a good agreement between cerebrospinal fluid (CSF)…
- Trial name
- BIOAMS (NCT01485549)
- Where
- France
- Volunteers
- 48 people
- Sponsor
- University Hospital, Bordeaux
Multiple System Atrophy - Parkinsonian Subtype (MSA-P)
A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy
This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Multiple System Atrophy.
- Trial name
- NCT07289477
- Testing
- Human Dopaminergic Progenitor Cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- iRegene Therapeutics Co., Ltd.
Multiple System Atrophy
Medical Decision Making in Multiple System Atrophy
The goal of this clinical study is to evaluate the effects of a personalized symptomatic treatment plan integrated with monthly telemedicine and mobile palliative care interventions on a population of individuals diagnosed with…
- Trial name
- MeDeMSA (NCT06072105)
- Testing
- Telemedicine visits, Multidisciplinary, personalized symptomatic treatment
- Where
- Austria
- Volunteers
- 92 people
- Sponsor
- Medical University Innsbruck
Multiple System Atrophy, Progressive Supranuclear Palsy
Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)
NNIPPS is a clinical trial of riluzole (a drug previously shown to slow down the rate of progression og amyotrophic lateral sclerosis-ALS; Lou Gehrig's disease) involving nearly 800 people diagnosed with the 'parkinson plus'…
- Trial name
- NCT00211224
- Testing
- Riluzole
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- King's College London
Parkinson Disease (PD), MSA - Multiple System Atrophy
Test-retest Trial With [11C]MODAG-005 in PD or MSA and AMHC - Pilot Phase
This is an open-label, single-center Phase 1 study evaluating the safety, tolerability, and test-retest characteristics of [11C]MODAG-005, an investigational positron emission tomography/computed tomography (PET/CT) radioligand…
- Conditions
- Parkinson Disease (PD), MSA - Multiple System Atrophy, Healthy Adult Participants
- Trial name
- PIOSA (NCT07640542)
- Testing
- [11C]MODAG-005
- Where
- Germany
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
Atypical Parkinsonism, Dementia With Lewy Bodies
Focused Ultrasound Thalamotomy for Tremor Relief in Atypical Parkinsonism
The goal of this retrospective observational study is to describe the efficacy of focused ultrasound ventral-intermediate nucleus thalamotomy in patients with atypical parkinsonism.
- Conditions
- Atypical Parkinsonism, Dementia With Lewy Bodies, Multiple System Atrophy, MSA
- Trial name
- FUSAP (NCT06204575)
- Testing
- Data collection
- Where
- Israel
- Volunteers
- 8 people
- Sponsor
- Rambam Health Care Campus
Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy
Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy…
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
- Trial name
- NOH302 (NCT00633880)
- Testing
- Droxidopa
- Where
- 54 sites in United States, Australia and 2 more
- Volunteers
- 181 people
- Sponsor
- Chelsea Therapeutics
Multiple System Atrophy (MSA)
A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA.
- Trial name
- NCT05923866
- Testing
- ONO-2808
- Where
- 35 sites in United States, Japan
- Volunteers
- 92 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Parkinson's Disease (PD), Multiple System Atrophy (MSA)
[18F]ACI-15916 PET in α-synucleinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein α-synuclein [involved in some diseases such as Parkinson's disease, Lewy body dementia and Multiple…
- Conditions
- Parkinson's Disease (PD), Multiple System Atrophy (MSA), Dementia With Lewy Bodies (DLB)
- Trial name
- NCT06891703
- Testing
- [18F]ACI-15916
- Where
- Sweden
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
Parkinson Disease, Prodromal Stage
Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity
α-Synucleinopathies, including Parkinson's disease and dementia with Lewy bodies, are the second most common neurodegenerative diseases.
- Conditions
- Parkinson Disease, Prodromal Stage, Neurodegenerative Diseases, Basal Ganglia Diseases
- Trial name
- ALPHA-FIT (NCT07324330)
- Testing
- Increase of physical activity volume and intensity with the use of a motivational smartphone application
- Where
- Germany
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn
Multiple System Atrophy
A Biomarker Study of ATH434 in Participants With MSA
This study will assess the safety and efficacy of ATH434 in participants with a clinical diagnosis of Multiple System Atrophy
- Trial name
- NCT05864365
- Testing
- ATH434
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Alterity Therapeutics